Lxo Ireland Designated Activity Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lxo Ireland Designated Activity (US): 3 reconciled FDA prescription therapies (89.4% 2025 to 2030 cliff risk), $1.0M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure89.4%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$1.0M
2024 Medicare Part D Spend$868K
2024 Medicaid Spend$170K
California HCAI SB 17 Filings8 WAC filings (max 29.5% 2-yr change)